Answer
Xydalba (dalbavancin) is not recommended during pregnancy unless the expected benefit clearly justifies the potential risk to the foetus; there are no data in pregnant women, and animal studies have shown reproductive toxicity.
Sources for this answer
- Xydalba 500 mg powder for concentrate for solution for infusionADVANZ Pharma · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked